Answers are grounded in this paper and cite their sources.
Interviews reveal strategies to enhance nucleic acid therapeutic delivery, indicating challenges ahead.
“[...] there have been three key categories of strategies that have had a transformative impact on the field – chemical design, conjugation, and formulation-based approaches.”Jokūbas Leikauskas, Editor, BioInsights, speaks with Sasha Ebrahimi, Scientific Leader, Emerging Drug Delivery Platforms team at GSK, about advanced strategies to improve the developability and targeted delivery of nucleic acid therapeutics. In particular, they discuss emerging design-for-delivery approaches, such as ligand- and formulation-based multifunctional approaches for extrahepatic delivery. They also highlight key translational challenges such as immune activation, safety considerations under repeat dosing, and the growing need for scalable chemical and enzymatic synthesis methods to support increasingly complex oligonucleotide constructs.
No takes yet. Share an insight, caveat, or question.
Sasha B. Ebrahimi (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: